EICHORCondition: Plaque Psoriasis · Sponsor: Takeda
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Total Dermatology | Birmingham, Alabama, United States | — |
| University of Alabama Hospital - Whitaker Clinic - | Birmingham, Alabama, United States | — |
| Cahaba Dermatology Skin Health Center | Hoover, Alabama, United States | — |
| Medical Dermatology Specialists | Phoenix, Arizona, United States | — |
| Saguaro Dermatology Associates, LLC - Probity - PPDS | Phoenix, Arizona, United States | — |
| Noble Clinical Research | Tucson, Arizona, United States | — |
| Johnson Dermatology Clinic | Fort Smith, Arkansas, United States | — |
| Burke Pharmaceutical Research | Hot Springs, Arkansas, United States | — |
| Zenith Research, Inc. | Beverly Hills, California, United States | — |
| First OC Dermatology Research Inc. | Fountain Valley, California, United States | — |
| Center for Dermatology Clinical Research | Fremont, California, United States | — |
| Long Beach Research Institute | Long Beach, California, United States | — |
+ 266 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06550076